 Xiayuan Liang
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 286 | 1.180 |
Why?
| | Receptor Protein-Tyrosine Kinases | 8 | 2013 | 231 | 0.770 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 13 | 0.660 |
Why?
| | Gene Rearrangement | 3 | 2013 | 151 | 0.620 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 188 | 0.610 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1251 | 0.590 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 130 | 0.590 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 2 | 2013 | 22 | 0.590 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 10 | 0.590 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2018 | 20 | 0.580 |
Why?
| | Leukemoid Reaction | 1 | 2016 | 3 | 0.520 |
Why?
| | GATA1 Transcription Factor | 1 | 2016 | 18 | 0.520 |
Why?
| | Genetic Association Studies | 1 | 2018 | 372 | 0.500 |
Why?
| | Diseases in Twins | 1 | 2016 | 159 | 0.480 |
Why?
| | Point Mutation | 1 | 2016 | 237 | 0.480 |
Why?
| | Hyaluronan Receptors | 2 | 2002 | 103 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 162 | 0.360 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 60 | 0.320 |
Why?
| | Glycoproteins | 2 | 2002 | 356 | 0.320 |
Why?
| | Down Syndrome | 1 | 2016 | 506 | 0.320 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2363 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 5 | 2013 | 623 | 0.300 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 469 | 0.260 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2013 | 310 | 0.250 |
Why?
| | Flow Cytometry | 5 | 2018 | 1197 | 0.250 |
Why?
| | Chromosome Aberrations | 3 | 2018 | 160 | 0.240 |
Why?
| | Leukemia | 1 | 2008 | 244 | 0.240 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 98 | 0.240 |
Why?
| | Immunohistochemistry | 5 | 2013 | 1737 | 0.230 |
Why?
| | Hodgkin Disease | 1 | 2007 | 157 | 0.230 |
Why?
| | Skin Neoplasms | 2 | 2002 | 849 | 0.220 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2004 | 12 | 0.220 |
Why?
| | Proto-Oncogenes | 1 | 2004 | 28 | 0.220 |
Why?
| | Cytogenetic Analysis | 2 | 2020 | 34 | 0.220 |
Why?
| | Eye Neoplasms | 1 | 2003 | 28 | 0.200 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 17 | 0.200 |
Why?
| | Stem Cells | 1 | 2008 | 602 | 0.200 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 431 | 0.200 |
Why?
| | Child | 14 | 2020 | 22308 | 0.200 |
Why?
| | Lymphomatoid Papulosis | 1 | 2002 | 1 | 0.190 |
Why?
| | Anaplasia | 1 | 2002 | 7 | 0.190 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.170 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 41 | 0.170 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 88 | 0.170 |
Why?
| | Child, Preschool | 9 | 2019 | 11457 | 0.170 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 79 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2007 | 766 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2020 | 16273 | 0.150 |
Why?
| | Infant | 9 | 2019 | 9818 | 0.150 |
Why?
| | Castleman Disease | 1 | 2019 | 13 | 0.150 |
Why?
| | Male | 15 | 2021 | 69783 | 0.150 |
Why?
| | Translocation, Genetic | 2 | 2013 | 109 | 0.150 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 31 | 0.150 |
Why?
| | Karyotyping | 1 | 2018 | 104 | 0.150 |
Why?
| | Histocytochemistry | 1 | 2018 | 80 | 0.140 |
Why?
| | Humans | 25 | 2021 | 141187 | 0.140 |
Why?
| | Immunophenotyping | 3 | 2004 | 329 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1787 | 0.140 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 148 | 0.140 |
Why?
| | Pregnancy, Triplet | 1 | 2016 | 5 | 0.130 |
Why?
| | Female | 15 | 2021 | 75515 | 0.130 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 25 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 333 | 0.120 |
Why?
| | Transcription Factors | 1 | 2004 | 1703 | 0.120 |
Why?
| | Twins, Monozygotic | 1 | 2016 | 190 | 0.120 |
Why?
| | Prognosis | 4 | 2019 | 4073 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1081 | 0.110 |
Why?
| | RNA, Small Interfering | 3 | 2013 | 626 | 0.110 |
Why?
| | Trans-Activators | 1 | 2016 | 388 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 987 | 0.100 |
Why?
| | Databases, Factual | 1 | 2019 | 1444 | 0.100 |
Why?
| | c-Mer Tyrosine Kinase | 5 | 2013 | 41 | 0.100 |
Why?
| | Hypoproteinemia | 1 | 2012 | 5 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2021 | 6275 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 18 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2794 | 0.090 |
Why?
| | Adolescent | 6 | 2019 | 22007 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 204 | 0.090 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2012 | 60 | 0.090 |
Why?
| | Edema | 1 | 2012 | 131 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 419 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.080 |
Why?
| | Anterior Chamber | 1 | 2009 | 26 | 0.080 |
Why?
| | Shock, Hemorrhagic | 1 | 2011 | 190 | 0.080 |
Why?
| | Apoptosis | 2 | 2010 | 2574 | 0.080 |
Why?
| | Astrocytoma | 1 | 2010 | 131 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2008 | 1478 | 0.070 |
Why?
| | Eye Diseases | 1 | 2009 | 92 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 304 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4610 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 437 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2018 | 11120 | 0.070 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.070 |
Why?
| | Adenoids | 1 | 2007 | 12 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 294 | 0.060 |
Why?
| | Palatine Tonsil | 1 | 2007 | 55 | 0.060 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 17 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2006 | 112 | 0.060 |
Why?
| | Adult | 7 | 2019 | 39177 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 361 | 0.060 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 330 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.060 |
Why?
| | Immunocompromised Host | 1 | 2007 | 203 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 153 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 250 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 830 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 388 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2007 | 502 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2011 | 891 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1056 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 7070 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2004 | 70 | 0.050 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2003 | 20 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 209 | 0.050 |
Why?
| | RNA, Viral | 1 | 2007 | 693 | 0.050 |
Why?
| | Ki-1 Antigen | 1 | 2002 | 7 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1073 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2003 | 219 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2004 | 134 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2021 | 2180 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2013 | 55 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1304 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 133 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1243 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 674 | 0.040 |
Why?
| | Survival Rate | 2 | 2019 | 1970 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 325 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 302 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2021 | 368 | 0.040 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 66 | 0.040 |
Why?
| | Macrophages | 1 | 2006 | 1561 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2013 | 898 | 0.040 |
Why?
| | Autoantigens | 1 | 2021 | 422 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1274 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 959 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2070 | 0.030 |
Why?
| | Mice | 4 | 2021 | 18048 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3348 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2021 | 858 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 908 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 34434 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 350 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2793 | 0.030 |
Why?
| | Animals | 5 | 2021 | 37657 | 0.030 |
Why?
| | Autoantibodies | 1 | 2021 | 1470 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 2003 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3166 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3490 | 0.020 |
Why?
| | Aged | 2 | 2002 | 24574 | 0.020 |
Why?
| | Protein-Losing Enteropathies | 1 | 2012 | 10 | 0.020 |
Why?
| | Hypoalbuminemia | 1 | 2012 | 31 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1973 | 0.020 |
Why?
| | Platelet Activation | 1 | 2011 | 95 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2166 | 0.020 |
Why?
| | Suppuration | 1 | 2009 | 9 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 196 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5200 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 64 | 0.020 |
Why?
| | Injections, Spinal | 1 | 2009 | 108 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 93 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 10 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 367 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 600 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5144 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2890 | 0.020 |
Why?
| | Metalloproteases | 1 | 2006 | 42 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 245 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 79 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2006 | 138 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2520 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1129 | 0.020 |
Why?
| | Thromboembolism | 1 | 2006 | 118 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3469 | 0.010 |
Why?
| | Macrophage Activation | 1 | 2006 | 200 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 388 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 914 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5629 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2504 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5887 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 13673 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2006 | 1431 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1487 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5799 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2006 | 2002 | 0.010 |
Why?
|
|
Liang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|